Background
==========

Pheochromocytomas and paragangliomas (PGLs) are catecholamine-secreting tumors of neural crest origin that arise from the adrenal medulla or extra-adrenal sympathetic paraganglia respectively. In the last decade, identification of multiple susceptibility genes has revealed an extensive genetic heterogeneity of these tumors. Catecholamine secretion is usually unpredictable, resulting in hypertension, arrhythmias, and/or hyperglycemia, and therefore tumor resection remains the gold standard of treatment [@bib1]. Although long-term postoperative remission is usually encountered in patients with benign tumors and the survival rates are similar to those of the normal population, tumor recurrence has also been reported with a frequency of between 6 and 23% [@bib2]. The highest rate of recurrence is usually associated with familial syndromes such as multiple endocrine neoplasia type 2 (MEN2), neurofibromatosis type 1 or von Recklinghausen\'s disease, von Hippel--Lindau (VHL) disease, and hereditary pheochromocytoma--PGLs syndrome [@bib3]. All these syndromes are based on autosomal dominant inheritance. The first two are associated with germline mutations in tumor suppressor genes. *VHL* mutations, however, result in a pseudo-hypoxic state through decreased degradation of HIF (cluster 1 transcriptome) and PGLs are attributed to mutations in succinate dehydrogenase (SDH) subunit genes *SDHB*, *SDHC*, and *SDHD* that comprise portions of mitochondrial complex II [@bib4]. In the last four years, four new genes namely *SDHA*, *SDHAF2*, *MAX*, and *TMEM127* have also been found to be associated with predisposition to pheochromocytomas and PGLs [@bib1].

Bilateral adrenal pheochromocytomas have also been described in patients with Beckwith--Wiedemann syndrome (BWS), a pediatric overgrowth disorder, usually presenting with hemihypertrophy and involving predisposition to tumor development [@bib5] [@bib6] [@bib7] [@bib8]. It is caused by mutation or deletion of imprinted genes within the chromosome 11p15.5 region, which harbors the insulin-like growth factor 2 (*IGF2*) gene. Tumors associated with this syndrome are usually of embryonic origin, such as Wilms\' tumor, hepatoblastomas, and neuroblastomas [@bib4]. The incidence of malignancy in such patients is irrespective of the site with a rate of ∼7.5% [@bib4].

Case presentation
=================

A 33-year-old woman was admitted to the outpatient clinic in 2007 referring severe headaches refractory to painkillers, episodic, and paroxysmal hypertension associated with postural changes and palpitations.

From her medical record, the patient was diagnosed with a benign hepatoma at the age of six months and was treated with right hemihepatectomy and plastic surgery of the abdominal wall. At the age of six, the patient was diagnosed with pheochromocytoma of the left adrenal gland and was submitted to subtotal adrenalectomy. Four years later at the age of ten, a new pheochromocytoma was diagnosed at the right adrenal gland and was again treated with subtotal adrenalectomy. At the age of 17, a third pheochromocytoma was identified in the anatomic region of the left adrenal gland by meta-iodobenzylguanidine (MIBG) scintiscan and was also resected.

Investigation
=============

During her clinical examination in our center, the patient had right ipsilateral hemihypertrophy, significant leg length discrepancy (left leg, 85 cm and right leg, 92 cm), and abdominal wall defects ([Fig. 1](#fig1){ref-type="fig"}). At the time of admission, her blood pressure was 270/140 mmHg with a heart rate of 146 b.p.m. (sinus tachycardia). Remarkable findings from the laboratory examinations included significantly elevated 24 h urine 3-methoxy-4-hydroxymandelic acid, and fractionated metanephrine levels and increased plasma metanephrine levels ([Table 1](#tbl1){ref-type="table"}). A new pheochromocytoma was then clinically and biochemically suspected and magnetic resonance imaging (MRI) scan of the abdomen identified a tumor on the anatomic region of the left adrenal gland ([Fig. 2](#fig2){ref-type="fig"}a).
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###### 

Laboratory examinations during our first evaluation of the patient. Values in bold are out of the normal range

  ------------------------------------------------------------------------ --------------------
  Plasma total metaneprines (\<1.04 nmol/ml)                               **1.5 nmol/ml**
  24 h-urine -- fractionated metanephrines (NR; 126.8--1125.6 nmol/24 h)   **1750 nmol/24 h**
  24 h-urine -- VMA (NR; 1.5--6.5 mg/24 h)                                 **55.3 mg/24 h**
  Chromogranin A (NR; 0--5 nmol/l)                                         **17 nmol/l**
  Aldosterone (NR; \<776 pmol/l)                                           350 pmol/l
  PRA (NR; 0.12--2.7 ng/l per s)                                           1.8 ng/l per s
  Cortisol (NR; 171--536 nmol/l)                                           314 nmol/l
  ACTH (NR; 1.11--6 pmol/l)                                                3.5 pmol/l
  TSH (NR; 0.4--4.50 mU/l)                                                 2.2 mU/l
  Calcitonin (basal; \<8 pg/ml)                                            1.6 pg/ml
  Glucose (NR; 70--110 mg/dl)                                              92 mg/dl
  Creatinine (NR; 0.40--1.10 mg/dl)                                        0.45 mg/dl
  ESR (NR; 0--20 mm)                                                       12 mm
  Phosphate (NR; 2.7--4.5 mg/dl)                                           3.2 mg/dl
  Calcium (NR; 8.6--10.2 mg/dl)                                            9.60 mg/dl
  Mg (N; 1.7--2.2 mg/dl)                                                   2.0 mg/dl
  ALP (NR; 8.4--29.3 μg/l)                                                 18 μg/l
  PTH (NR; 1.0--6.5 pmol/l)                                                4.8 pmol/l
  WBC (Poly:Lym:Eos)                                                       7.66 (56:22:0.2)
  ------------------------------------------------------------------------ --------------------

VMA, vanillylmandelic acid; NR, normal range.
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Treatment
=========

Soon after diagnosis, resection of the tumor was performed ([Fig. 2](#fig2){ref-type="fig"}b).

Outcome and follow-up
=====================

Histopathological analyses revealed a well-circumscribed tumor of size 4.5 cm and weighing 90 g, with areas of cystic degeneration. There were no features of vascular invasion or extension into the periadrenal soft tissues and the tumor cells were arranged in the characteristic 'zellballen' architecture. The tumor demonstrated positive immunoreactivity for pheochromocytoma with chromogranin and synaptophysin and membrane immunoreactivity with CD56. The mitotic index was 0.4 mitoses per ten high power fields (HPFs) and no atypical mitotic forms were identified. The Ki-67 index was \<1%.

Following surgery, her blood pressure became normalized and at the fifth postoperative day she was discharged home without antihypertensive treatment. The patient did not require replacement therapy with hydrocortisone and/or fludrocortisone. The patient had regular visits every 6 months with measurement of blood arterial pressure and urine metanephrines.

Two years later, the patient presented again to the outpatient clinic complaining for tachycardia. The 24 h blood pressure (BP) measurement reveals normal blood pressure and a relevant tachycardia (100 b.p.m.). In laboratory examinations, the patient had elevated 24 h urine metanephrine and normetanephrine levels (1840 and 1693 nmol/24 h respectively) and we proceeded with MRI for the localization of the tumor. The MRI revealed the presence of a heterogeneous mass with the characteristic, for pheochromocytomas, high signal intensity on T2-weighted imaging in the anatomic region above the uterus, that most probably represents a locoregional recurrence after tumor spill. The patient was reluctant to undergo further surgery and she was discharged with antihypertensive treatment (α and β blockade).

Genetic analysis
----------------

Based on her clinical appearance (hemihypertrophy and abdominal wall defects) and her medical record, the diagnosis of BWS was suspected. According to the Children\'s Association of New Zealand [@bib9] [@bib10], the diagnosis of BWS is based on clinical suspicion and presence of two of the five major characteristics, namely macroglossia, unexplained hypoglycemia in the first 4 months of life, ear creases or pits, abdominal wall defect (including minor naval hernia), and birth weight over 90--95% (adjusted for prematurity if relevant).

However, genetic analysis did not confirm our clinical diagnosis. Multiplex ligation-dependent probe analysis revealed no epigenetic alterations in 11p15.5, which included investigation for hypomethylation at *KCNQ1OT1* and hypermethylation at *ICR1*, and also no 11p15.5 uniparental disomy (UPD) was found. Karyotyping with g-banding performed in the whole blood showed 46,XX chromosomes.

Discussion
==========

Multiple benign pheochromocytomas are rare in the general population, and the prevalence is not known. Malignant behavior is present in 10% of pheochromocytomas and currently, no absolute histomorphological, genetic, molecular, or immunohistochemical findings are available to differentiate between malignant and benign pheochromocytomas, except for the presence of distant metastases [@bib11]. Extensive local invasion and confluent tumor necrosis are 'suspicious' features.

In our case, there were no invasive tumors or any other signs of malignancy. However, due to the lack of definite criteria, the possibility of an unrecognized malignancy cannot be completely excluded.

Hemihypertrophy is usually associated with rare genetic syndromes such as Simpson--Golabi--Behmel syndrome, Costello syndrome, Perlman syndrome, Sotos syndrome, and mucopolysaccharidosis type V, although sporadic cases of idiopathic-isolated hemihypertrophy have also been reported [@bib12]. The latter was also characterized by genetic heterogeneity and has been referred as partial BWS [@bib9].

BWS is a rare congenital disorder characterized by hemihypertrophy, embryonic tumors, adrenocortical cytomegaly, ear anomalies (anterior linear earlobe creases and posterior helical pits), visceromegaly, renal abnormalities, neonatal hypoglycemia, cleft palate, and a positive family history [@bib7] [@bib9] [@bib13]. Occurrence is usually sporadic, but familial distribution has also been reported, with an incidence of ∼1:13 700 births [@bib4].

According to the literature, five cases describing the association of the syndrome with bilateral adrenal pheochromocytomas have been reported so far [@bib5] [@bib14] [@bib15] [@bib16] [@bib17]. The first case described a 20-year-old female patient in whom BWS was diagnosed within a few days of birth from the association of hydramnios, omphalocele, right hemihypertrophy affecting the pelvis and upper and lower limbs, hepatomegaly, and episodes of hypoglycemia. The patient presented with high blood pressure and bilateral pheochromocytoma and was treated successfully with laparoscopic operation [@bib14]. In another case report, a 6-year-old boy with BWS presented with hypertension, tachycardia, and enlarged adrenal glands, and resection of the larger right adrenal gland revealed three nodular lesions histologically compatible with multifocal pheochromocytoma [@bib5]. The third report involves a girl with BWS without hypertension that was diagnosed with pheochromocytoma and had adrenalectomy at the age of 8 years. Consequently, after seven months, she developed a second pheochromocytoma that was again resected. The patient had stenosis of multiple large and medium arteries including the carotid, the renal, and the celiac artery. Her subsequent course included a right hemiplegic stroke and recurrent transient ischemic attacks [@bib15].

The fourth case represents a very similar case to the present, involving a 19-year-old female with congenital hemihypertrophy and bilateral benign pheochromocytoma. In this patient, screening for MEN2A and MEN2B in the DNA of peripheral blood lymphocytes was negative. Screening for somatic and germline mutations in the *VHL* and *RET* genes in the adrenal tumor was also negative and methylation patterns for *LIT1* (*KCNQ1OT1*) and *H19* genes associated with BWS were normal. After bilateral adrenalectomy, the patient received hormonal substitution for adrenal deficiency and yearly screening of urinary catecholamines was advised [@bib16].

The fifth case involved early-onset bilateral pediatric pheochromocytomas caused by mosaic chromosome 11p15 paternal UPD, which was recently reported. It involves an 18-month-old girl, who at the age of 4 months presented with bilateral pheochromocytomas [@bib17].

Patients with BWS may exhibit other adrenal tumors as well. Alsultan *et al*. described a case of a 6-month-old patient with bilateral adrenal tumors and increased MIBG uptake within the left adrenal tumor. However, histology revealed a neuroblastoma on the left adrenal and an atypical adrenocortical tumor on the right [@bib18]. Similarly, Beauloye *et al*. presented bilateral asynchronous adrenal adenomas in a girl with an incomplete form of BWS. In this case, 24-h urinary 17-ketosteroids, as well as plasma androgens, were elevated and both tumors showed the same atypical histomorphology after resection [@bib19].

It was found that 85% of BWS cases are karyotypically normal. The genetic background is associated, although not always diagnostic, with mutations or deletions of imprinted genes within the chromosomic region 11p15.5. Five imprinted genes have demonstrated causal relationship: *IGF2*, *H19*, cyclin-dependent kinase inhibitor 1C (*CDKN1C*), potassium voltage-gated channel, KQT-like subfamily, member 1 (*KCNQ1*), and *KCNQ1* overlapping transcript 1 (*KCNQ1OT1*). The only mutations within a gene are loss-of-function mutations in the *CDKN1C* gene, which encodes for a cell cycle regulator [@bib20]. *CDKN1C* mutations appear to be particularly associated with umbilical abnormalities, but not with increased predisposition to Wilms\' tumor. Epigenetic factors have also been reported including UPD of 11p15, hypomethylation of *KCNQ1OT1* gene, and hypermethylation of the genes *H19*, *LIT1*, and *IGF2* [@bib20].

Tested epigenetic alterations were not indicative of BWS in our patient. However, epigenetic alterations may be supportive to the clinical diagnosis but cannot definitively exclude the syndrome. There may be a wide heterogeneity for epimutations regarding BWS, as the causative genetic factors are still unknown.

Our patient is a rare case presenting with multiple recurrent benign pheochromocytomas associated with hemihypertrophy. Although we were not able to reach a definite diagnosis with genetic confirmation, a partial BWS with idiopathic hemihypertrophy (BWS/HH) seems to be the most plausible diagnosis. Other syndromes that are associated with hemihypertrophy usually have distinctive facial or cerebral features and mental retardation, which was not the case for our patient.

Cases of benign recurrent pheochromocytomas can be part of rare congenital syndromes and further genetic research is warranted in order to identify novel disease genes and shed light into complex clinical cases that remain undiagnosed. Timely follow-up of the patient\'s blood pressure and resection of the tumor when able to localize remain the gold standard in the therapeutic approach of these patients.
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